Triple-negative breast cancer is a highly aggressive subtype of breast cancer that affects 10% - 15% of all breast cancer patients. According to the American Cancer Society, Black women are more than twice as likely as other ethnic populations to receive a diagnosis of triple-negative breast cancer.
Stefan Bossmann, Ph.D., professor and chair of the Department of Cancer Biology at the University of Kansas Medical Center, was selected by the National Academy of Inventors (NAI) to join the 2025 class of senior members. He is the first senior member from KU Medical Center. The academy recognizes and promotes academic invention.
Researchers are leading a multicenter trial, funded by a five-year, nearly $4 million grant awarded last fall by the National Institutes of Health, to tackle food insecurity in people with blood cancers who are receiving transplant or cellular therapy.
The University of Kansas Medical Center is partnering with the University of Wisconsin Center for Tobacco Research and Intervention to determine what treatments work best to help Black people to quit smoking. Their research is funded with a $10 million award from the Patient-Centered Outcomes Research Institute.
Childhood trauma can increase a breast cancer survivor鈥檚 chance of experiencing more severe and longer-lasting treatment-related anxiety, depression and fatigue, as well as reduced cognitive function, years after cancer treatment has ended, according to a preliminary study led by Jamie Myers, Ph.D., FAAN, research associate professor at the University of Kansas School of Nursing.
A researcher at The University of Kansas Cancer Center is leading a national clinical trial to test a combination vaccine to prevent colon cancer in people with Lynch syndrome.
Study Finds Opt-Out Treatment Helps Smokers Quit, Even Those with Low Motivation
The University of Kansas Cancer Center is part of the myeloMATCH trial, a large, coordinated effort to improve patient outcomes through targeted treatments for people with acute myeloid leukemia or myelodysplastic syndrome.
Researchers at The University of Kansas Cancer Center have secured a $3.6 million grant from the U.S. Department of Defense to study high-dose intravenous Vitamin C for treating muscle-invasive bladder cancer. This type of cancer occurs when cancer cells spread to the muscle layer of the bladder wall.
Anthony Sung, MD, has been named the A. Drue Jennings Professor in Medical Oncology and the director of the Center for Survivorship and Patient-Oriented Research at The University of Kansas Cancer Center.
The Kansas Institute for Precision Medicine (KIPM) will continue its mission to improve health care by training physicians and scientists in precision medicine and supporting their research, thanks to a renewed Centers of Biomedical Research Excellence (COBRE) award from the National Institute of General Medical Sciences, part of the National Institutes of Health.
Benyi Li, MD, PhD, professor in the Department of Urology and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense to develop a short peptide-based therapy for prostate cancer patients.
Pool Cool is a program designed to educate young people in The University of Kansas Cancer Center鈥檚 catchment area on sun safety behaviors.
A researcher at The University of Kansas Cancer Center has received a $930,000 grant from the U.S. Department of Defense to study a new targeted therapy option for people diagnosed with ductal carcinoma in situ (DCIS).
In order to grow and train future clinical and translational scientists, The University of Kansas Cancer Center has received a $2.4 million grant from the National Cancer Institute (NCI).
The University of Kansas Cancer Center has received a $100 million lead gift to build a new, state-of-the-art destination cancer center. This gift is both the largest gift ever given by the Sunderland Foundation and the largest ever received by the University of Kansas and The University of Kansas Health System.
Chimeric antigen receptor (CAR) T-cell therapy amplifies the immune system鈥檚 ability to recognize and kill cancer cells. The first CAR T-cell therapy was approved by the Food and Drug Administration (FDA) in 2017. Today, there are 6 FDA-approved CAR-based therapies to treat certain types of leukemia, lymphoma and myeloma, all of which are available at The University of Kansas Cancer Center.
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center鈥檚 broader campaign to increase the participation of minority and underserved populations in clinical trials.
TEAMSPORT will create a standardized approach to ordering genomic tests and adapt it for use in community cancer centers, where most cancer patients receive testing and treatment.
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right